<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03358693</url>
  </required_header>
  <id_info>
    <org_study_id>A100/12</org_study_id>
    <nct_id>NCT03358693</nct_id>
  </id_info>
  <brief_title>Molecular Signatures in Inflammatory Skin Disease</brief_title>
  <acronym>MSID</acronym>
  <official_title>Systematic Profiling of Anti-cytokine Signatures in the Treatment of Chronic Inflammatory Skin Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Stephan Weidinger</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Schleswig-Holstein</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot project intends to examine the utility of a systems medicine approach to identify&#xD;
      regulatory networks and their perturbation in psoriasis and atopic dermatitis, and to obtain&#xD;
      a comprehensive perspective on disease and disease control by integrating and modelling data&#xD;
      across multiple cellular levels and time following specific blockade of single&#xD;
      pathophysiological factors through use of licensed biologics during routine care as systems&#xD;
      biology challenge. To this end, ultra-deep phenotyping and prospective molecular&#xD;
      characterization in short time-intervals and different disease equilibrium states will be&#xD;
      carried out in targeted small sets of patients. The different layers and types of clinical&#xD;
      and molecular information will then be integrated (integrative personal omics profiling iPOP)&#xD;
      for generating insights into disease pathways and for extraction of molecular signatures that&#xD;
      correspond to clinical severity scores. It will provide a good starting point for planning&#xD;
      future trials aimed at identifying biological patterns useful for guiding targeted treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of molecular signatures associated with treatment</measure>
    <time_frame>Baseline and day 1, day 7, day 14, day 84, day 112</time_frame>
    <description>Changes of transcriptome and microbiome signatures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of molecular signatures associated with treatment response</measure>
    <time_frame>Baseline and day 1, day 7, day 14, day 84, day 112</time_frame>
    <description>Changes of transcriptome and microbiome signatures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of molecular signatures associated with disease severity/remission</measure>
    <time_frame>Baseline and day 1, day 7, day 14, day 84, day 112</time_frame>
    <description>Changes of transcriptome and microbiome signatures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Eczema area and severity index (EASI) score</measure>
    <time_frame>Baseline and day 1, day 7, day 14, day 42, day 84, day 112</time_frame>
    <description>Clinical severity score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Score of Atopic Dermatitis (SCORAD)</measure>
    <time_frame>Baseline and day 1, day 7, day 14, day 42, day 84, day 112</time_frame>
    <description>Clinical severity score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Psoriasis Area Severity Index (PASI) score</measure>
    <time_frame>Baseline and day 1, day 7, day 14, day 42, day 84, day 112</time_frame>
    <description>Clinical severity score</description>
  </secondary_outcome>
  <number_of_groups>10</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Atopic Dermatitis</condition>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Psoriasis patients receiving ustekinumab</arm_group_label>
    <description>Ustekinumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psoriasis patients receiving infliximab</arm_group_label>
    <description>Infliximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psoriasis patients receiving secukinumab</arm_group_label>
    <description>Secukinumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atopic dermatitis patients receiving dupilumab</arm_group_label>
    <description>Dupilumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psoriasis patients receiving brodalumab</arm_group_label>
    <description>Brodalumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psoriasis patients receiving Ixekizumab</arm_group_label>
    <description>Ixekizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atopic dermatitis patients receiving tralokinumab</arm_group_label>
    <description>Tralokinumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atopic dermatitis patients receiving baricitinib</arm_group_label>
    <description>Baricitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atopic dermatitis patients receiving abrocitinib</arm_group_label>
    <description>Abrocitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atopic dermatitis patients receiving upadacitinib</arm_group_label>
    <description>Upadacitinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab</intervention_name>
    <description>Subject receives Ustekinumab open-label as per guidelines</description>
    <arm_group_label>Psoriasis patients receiving ustekinumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>Subject receives Infliximab open-label as per guidelines</description>
    <arm_group_label>Psoriasis patients receiving infliximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>Subject receives Secukinumab open-label as per guidelines</description>
    <arm_group_label>Psoriasis patients receiving secukinumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab</intervention_name>
    <description>Subject receives Dupilumab open-label as per guidelines</description>
    <arm_group_label>Atopic dermatitis patients receiving dupilumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brodalumab</intervention_name>
    <description>Subject receives Brodalumab open-label as per guidelines</description>
    <arm_group_label>Psoriasis patients receiving brodalumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixekizumab</intervention_name>
    <description>Subject receives Ixekizumab open-label as per guidelines</description>
    <arm_group_label>Psoriasis patients receiving Ixekizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib</intervention_name>
    <description>Subject receives Baricitinib open-label as per guidelines</description>
    <arm_group_label>Atopic dermatitis patients receiving baricitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abrocitinib</intervention_name>
    <description>Subject receives Abrocitinib open-label as per guidelines</description>
    <arm_group_label>Atopic dermatitis patients receiving abrocitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Upadacitinib</intervention_name>
    <description>Subject receives Upadacitinib open-label as per guidelines</description>
    <arm_group_label>Atopic dermatitis patients receiving upadacitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tralokinumab</intervention_name>
    <description>Subject receives Tralokinumab open-label as per guidelines</description>
    <arm_group_label>Atopic dermatitis patients receiving tralokinumab</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, skin biopsies, swabs, tape strips, stool&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with moderate to severe psoriasis or atopic dermatitis who receive specified&#xD;
        biologics from their treating dermatologist during routine care&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to provide written informed consent and comply with the protocol&#xD;
&#xD;
          -  At least 18 years of age.&#xD;
&#xD;
          -  Diagnosis of chronic psoriasis or atopic dermatitis for at least 3 years prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  PASI score ≥ 10 or EASI score ≥ 16&#xD;
&#xD;
          -  Investigator Global Assessment (IGA) ≥ 3&#xD;
&#xD;
          -  Subject receives systemic therapy within routine care (in-label use of biologics)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is unable to provide written informed consent or comply with the protocol.&#xD;
&#xD;
          -  Subject is younger than 18 years of age.&#xD;
&#xD;
          -  Subject has had psoriasis or atopic dermatitis for less than 3 years prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Subject with mild psoriasis or atopic dermatitis (PASI&lt;16 or EASI&lt;16 and IGA&lt;3) or is&#xD;
             not a candidate or is not eligible for systemic treatment&#xD;
&#xD;
          -  Having used immunosuppressive/immunomodulating therapy or phototherapy within 4 weeks&#xD;
             before the baseline visit.&#xD;
&#xD;
          -  Treatment of selected skin areas to be examined with topical corticosteroid or topical&#xD;
             calcineurin inhibitor within 1 week before the baseline visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Stephan Weidinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology, university Hospital Schleswig-Holstein, Campus Kiel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephan Weidinger, MD</last_name>
    <email>sweidinger@dermatology.uni-kiel.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sascha Gerdes, MD</last_name>
    <email>sgerdes@dermatology.uni-kiel.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Dermatology, University Hospital Schleswig Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Weidinger, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Sascha Gerdes, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 4, 2017</study_first_submitted>
  <study_first_submitted_qc>November 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2017</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Schleswig-Holstein</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Stephan Weidinger</investigator_full_name>
    <investigator_title>Head, Inflammatory Skin Disease Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Upadacitinib</mesh_term>
    <mesh_term>Ustekinumab</mesh_term>
    <mesh_term>Ixekizumab</mesh_term>
    <mesh_term>Brodalumab</mesh_term>
    <mesh_term>Abrocitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

